Galimedix Therapeutics is a Phase 2 neuropharmaceutical company developing novel first-in-class drugs with ground-breaking potential to slow or stop the progression of neurodegeneration and to improve function in glaucoma and dry AMD – leading causes of blindness – and also in Alzheimer’s disease.
This company has no teams yet